BridgeBio Pharma, Inc.
US ˙ NasdaqGS ˙ US10806X1028

SecurityBBIO / BridgeBio Pharma, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Barclays Plc ownership in BBIO / BridgeBio Pharma, Inc.

On May 15, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 0 shares of BridgeBio Pharma, Inc. (US:BBIO) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 622,575 shares of BridgeBio Pharma, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (BBIO) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

BBIO / BridgeBio Pharma, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 0 -622,575 -100.00 0 -100.00
2026-02-13 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 622,575 -96,873 -13.46 47,621 27.44 0.0114
2026-03-31 2025-09-30 13F/A-3 BRIDGEBIO PHARMA COM 10806X102 719,448 -214,064 -22.93 37,368 -7.30 0.0081
2026-03-19 2025-09-30 13F/A-2 BRIDGEBIO PHARMA COM 10806X102 545,008 -388,504 13,876 0.0037
2025-11-12 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 719,448 -214,064 37,368 0.0081
2026-02-27 2025-06-30 13F/A-2 BRIDGEBIO PHARMA COM 10806X102 933,512 544,674 140.08 40,309 199.87 0.0092
2025-08-14 2025-06-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 933,512 544,674 40 0.0092
2025-08-13 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 933,512 544,674 40 0.0030
2026-03-17 2025-03-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 388,838 -58,672 -13.11 13,442 9.47 0.0038
2025-05-15 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 388,838 -58,672 13 0.0038
2026-03-19 2024-12-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 447,510 -97,498 -17.89 12,280 -11.50 0.0034
2025-02-13 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 447,510 -97,498 12 0.0034
2026-03-31 2024-09-30 13F/A-2 BRIDGEBIO PHARMA COM 10806X102 545,008 131,743 31.88 13,876 32.55 0.0037
2024-11-19 2024-09-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 545,008 131,743 14 0.0037
2024-11-15 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 545,008 131,743 14 0.0037
2026-03-23 2024-06-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 413,265 8,097 2.00 10,468 -16.44 0.0032
2024-08-14 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 413,265 8,097 10 0.0032
2026-03-24 2024-03-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 405,168 -336,870 -45.40 12,528 -58.18 0.0044
2024-05-15 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 405,168 -336,870 13 0.0044
2026-03-25 2023-12-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 742,038 260,598 54.13 29,956 135.97 0.0110
2024-02-15 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 742,038 260,598 30 0.0110
2026-03-26 2023-09-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 481,440 -107,724 -18.28 12,696 25.28 0.0079
2023-11-07 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 481,440 -107,724 13 0.0079
2026-03-30 2023-06-30 13F/A-2 BRIDGEBIO PHARMA COM 10806X102 589,164 -81,715 -12.18 10,134 -8.90 0.0064
2023-09-20 2023-06-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 589,164 -81,715 10 0.0064
2023-08-03 2023-06-30 13F BRIDGEBIO PHARMA COM 10806X102 589,164 -81,715 10 0.0064
2026-03-30 2023-03-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 670,879 -531,006 -44.18 11,123 21.46 0.0051
2023-05-04 2023-03-31 13F BRIDGEBIO PHARMA COM 10806X102 670,879 -531,006 11 0.0051
2026-03-30 2022-12-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,201,885 875,468 268.21 9,158 182.31 0.0041
2023-02-13 2022-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,201,885 875,468 9 0.0041
2022-11-03 2022-09-30 13F BRIDGEBIO PHARMA COM 10806X102 326,417 296,979 1,008.83 3,244 1,110.45 0.0035
2022-08-12 2022-06-30 13F BRIDGEBIO PHARMA COM 10806X102 29,438 -13,148 -30.87 268 -37.96 0.0002
2022-05-16 2022-03-31 13F BRIDGEBIO PHARMA COM 10806X102 42,586 -151,488 -78.06 432 -86.65 0.0003
2022-02-23 2021-12-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 194,074 104,508 116.68 3,237 -22.87 0.0012
2022-02-14 2021-12-31 13F BRIDGEBIO PHARMA COM 10806X102 194,074 104,508 3,237 0.0004
2021-11-09 2021-09-30 13F BRIDGEBIO PHARMA COM 10806X102 89,566 26,546 42.12 4,197 9.24 0.0019
2021-08-13 2021-06-30 13F BRIDGEBIO PHARMA COM 10806X102 63,020 -37,199 -37.12 3,842 -37.77 0.0018
2021-05-13 2021-03-31 13F BRIDGEBIO PHARMA COM 10806X102 100,219 63,771 174.96 6,174 138.19 0.0033
2021-02-11 2020-12-31 13F BRIDGEBIO PHARMA COM 10806X102 36,448 3,076 9.22 2,592 107.03 0.0014
2020-11-12 2020-09-30 13F BRIDGEBIO PHARMA COM 10806X102 33,372 -12,116 -26.64 1,252 -15.63 0.0007
2020-08-12 2020-06-30 13F BRIDGEBIO PHARMA COM 10806X102 45,488 16,124 54.91 1,484 74.38 0.0011
2020-05-13 2020-03-31 13F BRIDGEBIO PHARMA COM 10806X102 29,364 3,230 12.36 851 -7.10 0.0007
2020-02-10 2019-12-31 13F BRIDGEBIO PHARMA COM 10806X102 26,134 12,431 90.72 916 211.56 0.0005
2019-11-15 2019-09-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 13,703 -3,631 -20.95 294 -37.04 0.0002
2019-11-14 2019-09-30 13F BRIDGEBIO PHARMA COM 10806X102 13,703 -3,631 294 67.9731
2019-08-14 2019-06-30 13F BRIDGEBIO PHARMA COM 10806X102 17,334 17,334 467 0.0003
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-03-23 2024-06-30 13F/A BRIDGEBIO PHARMA OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F BRIDGEBIO PHARMA OPT Call 0 0 n/a n/a n/a
2026-03-24 2024-03-31 13F/A BRIDGEBIO PHARMA OPT Call 30,000 928 n/a n/a n/a
2024-05-15 2024-03-31 13F BRIDGEBIO PHARMA OPT Call 30,000 1 n/a n/a n/a
2023-09-21 2023-06-30 13F/A BRIDGEBIO PHARMA OPT Call 0 0 n/a n/a n/a
2026-03-30 2023-06-30 13F/A BRIDGEBIO PHARMA OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-03 2023-06-30 13F BRIDGEBIO PHARMA OPT Call 0 0 n/a n/a n/a
2026-03-30 2023-03-31 13F/A BRIDGEBIO PHARMA OPT Call 2,100 35 n/a n/a n/a
2023-05-04 2023-03-31 13F BRIDGEBIO PHARMA OPT Call 2,100 0 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F BRIDGEBIO PHARMA OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-13 2025-12-31 13F BRIDGEBIO PHARMA OPT Put 20,400 0.00 1,560 47.31 n/a n/a n/a
2026-03-31 2025-09-30 13F/A BRIDGEBIO PHARMA OPT Put 20,400 1,060 n/a n/a n/a
2025-11-12 2025-09-30 13F BRIDGEBIO PHARMA OPT Put 20,400 1,060 n/a n/a n/a
2026-03-23 2024-06-30 13F/A BRIDGEBIO PHARMA OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F BRIDGEBIO PHARMA OPT Put 0 0 n/a n/a n/a
2026-03-24 2024-03-31 13F/A BRIDGEBIO PHARMA OPT Put 36,500 461.54 1,129 330.53 n/a n/a n/a
2024-05-15 2024-03-31 13F BRIDGEBIO PHARMA OPT Put 36,500 1 n/a n/a n/a
2026-03-25 2023-12-31 13F/A BRIDGEBIO PHARMA OPT Put 6,500 262 n/a n/a n/a
2024-02-15 2023-12-31 13F BRIDGEBIO PHARMA OPT Put 6,500 0 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.